Hemab Therapeutics (NASDAQ:COAG) Stock Price Down 7.2% – Here’s Why

Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG)’s stock price fell 7.2% on Tuesday . The stock traded as low as $25.01 and last traded at $25.19. 54,928 shares were traded during trading, a decline of 79% from the average session volume of 257,588 shares. The stock had previously closed at $27.15.

Analysts Set New Price Targets

Separately, Wall Street Zen raised Hemab Therapeutics to a “hold” rating in a research note on Saturday, May 9th.

Hemab Therapeutics Price Performance

Insider Activity at Hemab Therapeutics

In other news, major shareholder Ra Capital Management, L.P. purchased 6,387 shares of the stock in a transaction that occurred on Tuesday, May 12th. The stock was acquired at an average price of $24.90 per share, with a total value of $159,036.30. Following the purchase, the insider owned 6,372,170 shares in the company, valued at $158,667,033. This represents a 0.10% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last three months, insiders purchased 2,898,074 shares of company stock valued at $53,650,008.

Hemab Therapeutics Company Profile

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.

Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.